Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
212 Pb-ADVC001 / AdvanCell Isotopes
ACTRN12622001378718: An early phase clinical trial to measure the safe dose of a new alpha-radiopharmaceutical for the treatment of advanced prostate cancer	Recruiting	1/2	18			AdvanCell Isotopes Pty Ltd, AdvanCell Isotopes Pty Ltd	Metastatic Prostate Cancer
NCT05720130: Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).	Recruiting	1/2	100	RoW	[²¹²Pb]Pb-ADVC001	AdvanCell Isotopes Pty Limited	Prostate Cancer, Metastatic Castration-resistant Prostate Cancer	12/27	12/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
212 Pb-ADVC001 / AdvanCell Isotopes
ACTRN12622001378718: An early phase clinical trial to measure the safe dose of a new alpha-radiopharmaceutical for the treatment of advanced prostate cancer	Recruiting	1/2	18			AdvanCell Isotopes Pty Ltd, AdvanCell Isotopes Pty Ltd	Metastatic Prostate Cancer
NCT05720130: Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).	Recruiting	1/2	100	RoW	[²¹²Pb]Pb-ADVC001	AdvanCell Isotopes Pty Limited	Prostate Cancer, Metastatic Castration-resistant Prostate Cancer	12/27	12/29